1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the biosimilars market
3.4 Related Markets
3.4.1 Over the counter drugs
3.4.2 Orphan drugs
3.4.3 Human Insulin
4 Market Outlook
4.1 Biosimilar products approved in US
4.2 Biosimilar products approved in Europe
4.3 Biologics patent expiration in US and Europe (2010-2020)
4.4 Market segmentation
4.5 PEST Analysis
4.6 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO – Global Biosimilars Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing incidence of disease
5.1.1.2 Cost-effectiveness of biosimilars than biologics
5.1.1.3 Strategic collaboration to develop new biosimilar drugs
5.1.2 Opportunities
5.1.2.1 Promising pipeline of biosimilars
5.1.2.2 Opportunities in emerging market
5.1.3 Restraints
5.1.3.1 Limited obtainability of biosimilar products
5.1.3.2 Difficult manufacturing process and high development cost
6 Product: Market Size and Analysis
6.1 Overview
6.2 Recombinant glycosylated proteins
6.2.1 Monoclonal antibody
6.2.2 Erythropoietin
6.3 Recombinant non-glycosylated proteins
6.3.1 Recombinant human growth hormone
6.3.2 Granulocyte colony stimulating factor
6.3.3 Insulin
6.3.4 Interferon
6.4 Recombinant peptides and others
7 Application: Market Size and Analysis
7.1 Overview
7.2 Cancer
7.3 Blood disorders
7.4 Chronic and immune disease
7.5 Infectious disease
7.6 Others
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.2.1 US 52
8.2.2 Canada
8.3 Europe
8.3.1 UK 54
8.3.2 Germany
8.3.3 France
8.3.4 Spain
8.4 Asia Pacific
8.4.1 India
8.4.2 China
8.4.3 Japan
8.5 Rest of the World
9 Competitive Landscape
9.1 Overview
10 Vendor Profiles
10.1 Pfizer, Inc.,
10.1.1 Overview
10.1.2 Business Units
10.1.3 Geographic Presence
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 Novartis AG
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Celltrion Healthcare
10.3.1 Overview
10.3.2 Business Focus
10.3.3 SWOT Analysis
10.3.4 Business Strategy
10.4 Dr. Reddy’s Laboratories Limited
10.4.1 Overview
10.4.2 Business Unit
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategy
10.5 Biocon Ltd
10.5.1 Overview
10.5.2 Business Unit
10.5.3 Geographic Presence
10.5.4 Business focus
10.5.5 SWOT analysis
10.5.6 Business Strategy
10.6 Teva Pharmaceutical Industries Ltd.
10.6.1 Overview
10.6.2 Business Unit
10.6.3 Geographic Presence
10.6.4 Business focus
10.6.5 SWOT analysis
10.6.6 Business Strategy
10.7 STADA Arzneimittel AG
10.7.1 Overview
10.7.2 Business Unit
10.7.3 Geographic Presence
10.7.4 Business focus
10.7.5 SWOT analysis
10.7.6 Business Strategy
11 Companies to Watch For
11.1 Amgen Inc.
11.1.1 Overview
11.2 Mylan N.V.
11.2.1 Overview
11.2.2 MYLAN N.V.: Recent Developments
11.3 Synthon Pharmaceuticals Inc.,
11.3.1 Overview
11.3.2 Synthon Pharmaceuticals Inc.: Recent Developments
11.4 Samsung Bioepis Co., Ltd.
11.4.1 Overview
11.4.2 SAMSUNG BIOEPIS CO., LTD: Recent Developments
12 Annexure
12.1 Abbreviations